News | November 18, 2021
Novavax and Serum Institute receive EUA for Covovax
The vaccine will be manufactured and marketed in the Philippines by SII under the brand name Covovax
The vaccine will be manufactured and marketed in the Philippines by SII under the brand name Covovax
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice
Filing marks first protein-based vaccine submitted to MHRA for authorization
It is a recombinant nanoparticle protein-based vaccine
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
Subscribe To Our Newsletter & Stay Updated
